Related references
Note: Only part of the references are listed.Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
Raphael J. Louie et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2019)
Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
Qiaofen Fu et al.
ONCOIMMUNOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience
Ivana Lameiras Gibbons et al.
ANAIS BRASILEIROS DE DERMATOLOGIA (2018)
Role of PD-1 during effector CD8 T cell differentiation
Eunseon Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study
T. Read et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz et al.
LABORATORY INVESTIGATION (2017)
Prognostic significance of PD-L1 in solid tumor An updated meta-analysis
Qianqian Wang et al.
MEDICINE (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
Nikki R. Adler et al.
BRITISH JOURNAL OF CANCER (2017)
Diagnosis and treatment of in-transit melanoma metastases
A. Testori et al.
EJSO (2017)
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
Michelle Chin I. Lo et al.
BRITISH JOURNAL OF CANCER (2016)
Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience
M. Moncrieff et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
Joseph M. Obeid et al.
ONCOIMMUNOLOGY (2016)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
Rebecca L. Read et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection
M. Picard et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy
Andrew P. Barbour et al.
EUROPEAN JOURNAL OF CANCER (2014)
Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights
Nicholas Gulati et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Topical Immunotherapy with Diphencyprone for in Transit and Cutaneously Metastatic Melanoma
Diona L. Damian et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Current Treatment of Locoregional Recurrence of Melanoma
Malcolm Hart Squires et al.
CURRENT ONCOLOGY REPORTS (2013)
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Sine Hadrup et al.
CANCER MICROENVIRONMENT (2013)
Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
Stephanie Moreau et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
J. -H. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Jill C. Rubinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience
Hidde M. Kroon et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone
Diona L. Damian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
